Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use of Pamrevlumab in Pancreatic Cancer
NCT02851381Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2016
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of pamrevlumab in pancreatic cancer (PC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Overall Survival at 7.7 months. Planned start Aug 2016; status: withdrawn.
02
Drugs
pamrevlumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02851381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02851381.